Arvinas, a biotechnology company developing two cancer-fighting drugs, recently raised $400 million in a stock offering.
After the company released clinical data regarding testing of its treatments being developed for metastatic breast cancer and prostate cancer “the demand for the stock became very high,” said Arvinas President and CEO John Houston.